Tuberculosis

• Date :
• 3    
  0

Tuberculosis

• Date :
• 2    
  0

PrEP persistence and associated factors: an analysis from the ANRS Prevenir study

• Date :
• 1    
  0

Hepatitis

• Date :
• 0    
  0

BHIVA late presentation audit: What can we learn?

• Date :
• 0    
  0

Results of the European pilot audit on Hepatitis screening, prevention and management in people living with HIV

• Date :
• 0    
  0

Equity-based data to support a strategic focus of HIV resource and programme prioritization

• Date :
• 0    
  0

Community engagement to generate demand for and deliver HIV and supportive services

• Date :
• 0    
  0

Addressing HIV and intersectional stigma as enemies of public health and barriers to progress

• Date :
• 0    
  0

Question & answer period

• Date :
• 0    
  0

Introduction : UNAIDS goals after 2020 – What next?

• Date :
• 0    
  0

Roundtable discussion: UNAIDS goals after 2020 - What next ?

• Date :
• 0    
  0

Combination prevention – The overview of what is being done in Europe

• Date :
• 0    
  0

Monitoring PrEP implementation in Belgium: national surveillance results, 2017-2018

• Date :
• 0    
  0

Micro-elimination of HCV – A reality?

• Date :
• 0    
  0

Giving HepC a place and letting it go again

• Date :
• 0    
  0

Impairment of CD8 T cell memory in DAA treated HCV/HIV co-infected patients

• Date :
• 0    
  0

Introduction

• Date :
• 0    
  0

Long-acting antiretroviral drugs

• Date :
• 0    
  0

Clinical case 1 - Complex DDIs

• Date :
• 0    
  0

Changes in bone mineral density over 2 years

• Date :
• 0    
  0

Evolution of non-invasive markers of liver fibrosis in HIV-hepatitis C virus (HCV)

• Date :
• 0    
  0

HIV/HBV coinfection in Spain: prevalence and clinical characteristics

• Date :
• 0    
  0

Outcomes after switching from TDF to TAF in HIV/HBV

• Date :
• 0    
  0

Clinical case 2 - Administration of drugs through feeding tube & absorption/DDIs issues

• Date :
• 0    
  0

Clinical case 3 - Cancer drugs DDIs

• Date :
• 0    
  0

Safety and PK of subcutaneous GS-6207, a novel HIV?1 capsid inhibitor

• Date :
• 0    
  0

Drop in HIV diagnoses among MSM in Paris

• Date :
• 0    
  0

Evolutive NAFLD predicts frailty in people living with HIV (PLWH)

• Date :
• 0    
  0

A multicentred randomised controlled open study of the utility and acceptability of a medicines optimisation review

• Date :
• 0    
  0

Prevalence of potential drug-drug interactions

• Date :
• 0    
  0

Causes of treatment failure in independent and industry-funded clinical trials

• Date :
• 0    
  0

Retrospective analysis of co-medication patterns among patients treated for HIV

• Date :
• 0    
  0

TDF/FTC is a cost-saving maintenance option in HIV-infected people with low reservoir

• Date :
• 0    
  0

Prevalence of and risk factors for low bone mineral density

• Date :
• 0    
  0

Restless legs syndrome and health-related quality of life in HIV

• Date :
• 0    
  0

Depression and kynurenine/tryptophan ratio in people living with HIV

• Date :
• 0    
  0

Antiretroviral therapy and clearance of oncogenic HPVs in HIV positive MSM

• Date :
• 0    
  0

Harnessing big data on Indonesian MSM and transgender individuals

• Date :
• 0    
  0

Prescription of antimicrobials in primary health care

• Date :
• 0    
  0

Adherence and clinical outcomes in asymptomatic patients starting ART

• Date :
• 0    
  0

Assessments of very low level HIV replication for dolutegravir+lamivudine

• Date :
• 0    
  0

Dolutegravir/emtricitabine dual therapy is non-inferior

• Date :
• 0    
  0

Risk of failure in dual therapy versus triple therapy in naïve HIV-patients

• Date :
• 0    
  0

Shorter time to treatment failure in PLHIV

• Date :
• 0    
  0

Epidemiology of HIV in Central and Eastern Europe

• Date :
• 0    
  0

Euroguidelines in Central and Eastern Europe

• Date :
• 0    
  0

Current trends in HIV/AIDS epidemic in Russia

• Date :
• 0    
  0

The burden of histoplasmosis and HIV: Connecting the dots

• Date :
• 0    
  0

Tuberculosis and HIV: recent advances and perspectives

• Date :
• 0    
  0

Frequency, presentation and predictors of strongyloidiasis

• Date :
• 0    
  0

Diagnosing tuberculosis in people living with HIV

• Date :
• 0    
  0

A New Health Care Index independently

• Date :
• 0    
  0

Panel discussion: Controversies in antiretroviral therapy

• Date :
• 0    
  0

Uptake and discontinuation of Integrase Inhibitors (INSTIs) in a large cohort setting

• Date :
• 0    
  0

Reaching the second and third UNAIDS 90-90-90 targets

• Date :
• 0    
  0

Comparison of TB drug susceptibility, treatment regimens and outcome among TB/HIV

• Date :
• 0    
  0

´Chems4EU´ a study describing chemsex use across 4 European countries

• Date :
• 0    
  0

Whole genome sequencing for tuberculosis treatment and control

• Date :
• 0    
  0

Precision medicine in HIV

• Date :
• 0    
  0

Introduction (Ageing with HIV)

• Date :
• 0    
  0

Do we need models of care for older people with HIV?

• Date :
• 0    
  0

Examples of models of care for older people with HIV in Europe

• Date :
• 0    
  0

Examples of models of care for older people with HIV in Europe : Italy

• Date :
• 0    
  0

Examples of models of care for older people with HIV in Europe : Poland

• Date :
• 0    
  0

Examples of models of care for older people with HIV in Europe : Norway

• Date :
• 0    
  0

Community perspective

• Date :
• 0    
  0

Closing (Ageing with HIV)

• Date :
• 0    
  0

Welcome ( EuroSIDA 25 years: What have we learned from cohort studies?)

• Date :
• 0    
  0

Major achievements in EuroSIDA : Perspective from invited expert

• Date :
• 0    
  0

The role of EuroSIDA in HIV, HCV and TB research in Central East and Eastern Europe

• Date :
• 0    
  0

What HIV observational cohorts have brought to the field

• Date :
• 0    
  0

Adapting HIV cohorts to future challenges in HIV research

• Date :
• 0    
  0

Questions/Wrap-up

• Date :
• 0    
  0

Welcome ( EACS Guidelines session )

• Date :
• 0    
  0

Introduction (EACS Guidelines session)

• Date :
• 0    
  0

ART panel

• Date :
• 0    
  0

Drug-drug interaction panel

• Date :
• 0    
  0

Co-morbidity panel

• Date :
• 0    
  0

Co-infection panel

• Date :
• 0    
  0

Opportunistic infections panel

• Date :
• 0    
  0

Community perspective

• Date :
• 0    
  0

Closing (EACS Guidelines session)

• Date :
• 0    
  0

Inflammation, the microbiome and HIV

• Date :
• 0    
  0

Neighbours visiting: Update from the 2019 co-morbidity workshop

• Date :
• 0    
  0

AIDS defining and non-defining cancers in persons living with HIV

• Date :
• 0    
  0

Global epidemiology of HIV and STI

• Date :
• 0    
  0

Framing the clinical issues

• Date :
• 0    
  0

STI in the era of PrEP and U=U

• Date :
• 0    
  0

RPV+DRV/cobi as 2DR option in HIV-infected subjects on virologic suppression

• Date :
• 0    
  0

Switching to DTG/3TC fixed dose combination (FDC)

• Date :
• 0    
  0

Phylogenetics as a tool in HIV research

• Date :
• 0    
  0

Stem-cell-like CD4+ memory T cells expand during the acute HIV-1 infection

• Date :
• 0    
  0

New and emerging STI concerns

• Date :
• 0    
  0

Considerations for key populations

• Date :
• 0    
  0

Safety and efficacy of triple therapy with Dolutegravir plus 2 NRTIs

• Date :
• 0    
  0

HIV-1-RNA kinetics in blood plasma and in seminal plasma of men

• Date :
• 0    
  0

Dolutegravir and lamivudine for maintenance of HIV viral suppression

• Date :
• 0    
  0

Incidence of CKD with TDF and non-TDF containing antiretroviral regimens

• Date :
• 0    
  0

The ADVANCE trial

• Date :
• 0    
  0

Pericardial adipose tissue volume is independently associated with HIV status

• Date :
• 0    
  0

Correlation between cerebrospinal fluid (CSF)

• Date :
• 0    
  0

TET2 genetic variation affects HIV viral load in ART-naïve persons

• Date :
• 0    
  0

Temporal evolution of a unique N332 supersite directed bnAb lineage

• Date :
• 0    
  0

The role of E6/7 mRNA for anal cancer screening

• Date :
• 0    
  0

Development and validation of a comorbidity index

• Date :
• 0    
  0

Prevalence of InSTI resistance and effectiveness of InSTI-based

• Date :
• 0    
  0

Modelling the syphilis epidemic among HIV-positive and negative MSM in Switzerland

• Date :
• 0    
  0

Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide

• Date :
• 0    
  0

In vitro analysis of doravirine activity on HIV-1 clones harboring multiple NNRTI

• Date :
• 0    
  0

89e Congrès de la Société Nationale de Médecine Interne

• Date :
• 1581    
  0

Les Rencontres des Maladies Rares - RARE 2023

• Date :
• 4454    
  0

86e Congrès de Société Nationale de Médecine Interne - SNFMI 2023

• Date :
• 10935    
  0

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

• Date :
• 3046    
  6

Colloque Scientifique Annuel de la Fondation Maladies Rares 2023

• Date :
• 5466    
  0